473 related articles for article (PubMed ID: 37501154)
1. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
2. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
Hays P
Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
[TBL] [Abstract][Full Text] [Related]
3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
4. Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.
Wang S; Peng L; Xu W; Zhou Y; Zhu Z; Kong Y; Leung S; Wang J; Yan X; Mi JQ
Front Med; 2022 Feb; 16(1):139-149. PubMed ID: 34463907
[TBL] [Abstract][Full Text] [Related]
5. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.
Tapia-Galisteo A; Compte M; Álvarez-Vallina L; Sanz L
Theranostics; 2023; 13(3):1028-1041. PubMed ID: 36793863
[TBL] [Abstract][Full Text] [Related]
6. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
[TBL] [Abstract][Full Text] [Related]
7. [Cancer therapy using bispecific antibodies].
Kadowaki N
Rinsho Ketsueki; 2018; 59(10):1942-1947. PubMed ID: 30305495
[TBL] [Abstract][Full Text] [Related]
8. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager.
Xiao X; Cheng Y; Zheng X; Fang Y; Zhang Y; Sun R; Tian Z; Sun H
Front Immunol; 2023; 14():1113303. PubMed ID: 37114050
[TBL] [Abstract][Full Text] [Related]
9. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
10. Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.
Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H
Front Immunol; 2021; 12():669496. PubMed ID: 34040611
[TBL] [Abstract][Full Text] [Related]
11. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
12. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
Gantke T; Weichel M; Herbrecht C; Reusch U; Ellwanger K; Fucek I; Eser M; Müller T; Griep R; Molkenthin V; Zhukovsky EA; Treder M
Protein Eng Des Sel; 2017 Sep; 30(9):673-684. PubMed ID: 28981915
[TBL] [Abstract][Full Text] [Related]
13. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
Meckler JF; Levis DJ; Vang DP; Tuscano JM
Cancer Immunol Immunother; 2023 Sep; 72(9):2939-2948. PubMed ID: 37247022
[TBL] [Abstract][Full Text] [Related]
14. Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells.
Kimura K; Kuwahara A; Suzuki S; Nakanishi T; Kumagai I; Asano R
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859608
[TBL] [Abstract][Full Text] [Related]
15. Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.
Debelec-Butuner B; Quitt O; Schreiber S; Momburg F; Wisskirchen K; Protzer U
Front Immunol; 2022; 13():1029214. PubMed ID: 36405686
[TBL] [Abstract][Full Text] [Related]
16. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
[TBL] [Abstract][Full Text] [Related]
17. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
18. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
19. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
20. [Recent progress of bispecific antibody-based therapy for hematological malignancies].
Ochi T
Rinsho Ketsueki; 2022; 63(9):1298-1309. PubMed ID: 36198556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
